Short Interest in Aadi Bioscience, Inc. (NASDAQ:AADI) Declines By 13.7%

Aadi Bioscience, Inc. (NASDAQ:AADI) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 472,700 shares, a decrease of 13.7% from the January 15th total of 547,500 shares. Approximately 2.3% of the shares of the company are sold short. Based on an average trading volume of 349,100 shares, the short-interest ratio is presently 1.4 days.

Aadi Bioscience Stock Down 4.0 %

NASDAQ:AADI traded down $0.12 on Monday, hitting $2.77. The stock had a trading volume of 129,967 shares, compared to its average volume of 251,684. The business’s 50-day simple moving average is $2.84 and its two-hundred day simple moving average is $2.19. The stock has a market cap of $68.16 million, a price-to-earnings ratio of -1.21 and a beta of 0.65. Aadi Bioscience has a 52-week low of $1.21 and a 52-week high of $3.81.

Aadi Bioscience (NASDAQ:AADI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.46) earnings per share for the quarter, hitting the consensus estimate of ($0.46). The business had revenue of $7.21 million for the quarter, compared to the consensus estimate of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same period last year, the firm earned ($0.60) earnings per share. As a group, equities research analysts anticipate that Aadi Bioscience will post -2.04 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new stake in Aadi Bioscience during the 3rd quarter valued at $32,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Aadi Bioscience in the second quarter valued at $37,000. Peapod Lane Capital LLC bought a new stake in shares of Aadi Bioscience in the 4th quarter worth about $1,397,000. Finally, BML Capital Management LLC bought a new stake in shares of Aadi Bioscience in the 3rd quarter worth about $4,120,000. 52.08% of the stock is currently owned by institutional investors.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.